Table 4.
List of Quality Assessment of Clinical Trials by PEDro Scale
| Author | RA | CA | BS | BP | BT | BA | 85% | IT | BC | MV | Total score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Meireles32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Basford33 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Brosseau34 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 9 |
| Stelian35 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Bulow36 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 7 |
| Gur37 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 9 |
| Tascioglu38 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Hegedus39 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 6 |
| Kulekcioglu41 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 6 |
| Venancio42 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 7 |
| Cetiner43 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 5 |
| Emshoff44 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Santos45 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 5 |
| Bingol50 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Stergioulas51 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 7 |
| Ozdemir40 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Chow52 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Klein46 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 7 |
| Soriano47 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 7 |
| Basford48 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Djavid2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Ay49 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
RA, random allocation; CA, concealed allocation; BS, baseline similarity; BP, blinding of patients; BT, blinding of therapists; BA, blinding of assessor; 85%, key outcome obtained from >85% of the initial subjects; IT, intentions to treat analysis; BC, between-group comparisons, MV, mean and variability data.